A literature review on off-label drug use in children

被引:300
作者
Pandolfini, C [1 ]
Bonati, M [1 ]
机构
[1] Mario Negri Inst Pharmacol Res, Lab Mother & Child Hlth, I-20157 Milan, Italy
关键词
drug; drug labelling; legislation; paediatrics; prescriptions;
D O I
10.1007/s00431-005-1698-8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The aim was to compare results of studies performed in different settings worldwide and identify common therapeutic areas to allow for focused interventions, because off-label drug use can be a measure of the lack of knowledge concerning paediatric treatments. A secondary objective was to provide a brief review of efforts to date. A literature review of articles on off-label and unlicensed drug use in children involving general prescription samples was performed using Medline and Embase. In all, 30 studies from 1985-2004 were included. Eleven involved paediatric hospital wards, seven neonatal hospital wards, and 12 the community setting. The off-label and unlicensed classification methods varied, making results difficult to compare. In general, off-label/unlicensed prescription rates ranged from 11%-80%, and higher rates were found in younger versus older patients and in the hospital versus community settings. On the paediatric hospital wards, off-label/unlicensed prescriptions ranged from 16%-62% and most often concerned acetaminophen, cisapride, chloral hydrate, and salbutamol. In the neonatal wards, rates ranged from 55%-80% and often involved caffeine. In the community setting, rates ranged from 11%-37% and the most commonly implicated drugs were salbutamol and amoxicillin. Conclusion:A lack of harmonisation between the evidence, the information available to doctors, and its use in clinical practice exists and this is part of the reason off-label therapies are so common. Attempts have been made to improve knowledge concerning paediatric treatments, but more focused interventions are needed, also taking into consideration this lack of harmonisation.
引用
收藏
页码:552 / 558
页数:7
相关论文
共 81 条
[1]   Incidence of prescriptions without product licence in a neonatal intensive care unit. [J].
Avenel, S ;
Bomkratz, A ;
Dassieu, G ;
Janaud, JC ;
Danan, C .
ARCHIVES DE PEDIATRIE, 2000, 7 (02) :143-147
[2]   Unlicensed and off-label medication use in a neonatal intensive care unit: A prospective study [J].
Barr, J ;
Brenner-Zada, G ;
Heiman, E ;
Pareth, G ;
Bulkowstein, M ;
Greenberg, R ;
Berkovitch, M .
AMERICAN JOURNAL OF PERINATOLOGY, 2002, 19 (02) :67-72
[3]   Off-label use of approved drugs: Therapeutic opportunity and challenges [J].
Bennett, WM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (03) :830-831
[4]   Is it time for a European formulary of paediatric medicines? [J].
Bonati, M ;
Pandolfini, C .
ARCHIVES OF DISEASE IN CHILDHOOD, 2004, 89 (09) :890-891
[5]  
BONATI M, 2004, PAEDIAT PERINAT DRUG, V6, P38
[6]  
BONATI M, 2003, 14 C EUR SOC AMB PAE
[7]  
Brion F, 2003, ACTA PAEDIATR, V92, P486
[8]   Off label prescribing to children in primary care in Germany:: retrospective cohort study [J].
Bücheler, R ;
Schwab, M ;
Mörike, K ;
Kalchthaler, B ;
Mohr, H ;
Schröder, H ;
Schwoerer, P ;
Gleiter, CH .
BRITISH MEDICAL JOURNAL, 2002, 324 (7349) :1311-1312
[9]   Research in children [J].
Burns, JP .
CRITICAL CARE MEDICINE, 2003, 31 (03) :S131-S136
[10]   Clinical trials in children [J].
Caldwell, PHY ;
Murphy, SB ;
Butow, PN ;
Craig, JC .
LANCET, 2004, 364 (9436) :803-811